ArticleACS nano2013
Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging.
Article in ACS nano, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Contrast-enhanced micro-computed tomography visualization of adhesively bonded CFRP/aluminum tubular joints.Nanoscale advances · 2026Article
- Ligand exchange on nanocrystals: fundamental mechanisms, regulation of nanocrystal properties, self-assembly, and advanced applications.Nanoscale advances · 2026Review
- Effect of sampling volume on measurements of size and chemical homogeneity of MRI contrast agent FeraSpin™ R.Nanoscale advances · 2026Article
- Synthesis of BSA-Coated Iron Oxide Nanoparticles with Size Control for High-PerformanceBiomolecules · 2026Article
- Radiolabeled Iron-Based Nanomaterials for Cancer Diagnosis and Therapy.International journal of nanomedicine · 2026Review
- Intelligent microstructure materials for diagnosis and treatment of osteoarthritis: progress and AI-enpowered future.Bone research · 2025Review
- Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.Future oncology (London, England) · 2025Review
- Piperazine-Derived Bisphosphonate-Based Ionizable Lipid Nanoparticles Enhance mRNA Delivery to the Bone Microenvironment.Angewandte Chemie (International ed. in English) · 2025Article
- Advances in Vascular Diagnostics using Magnetic Particle Imaging (MPI) for Blood Circulation Assessment.Advanced healthcare materials · 2024Review
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging.Drug delivery and translational research · 2023Review
- Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI.Nanomaterials (Basel, Switzerland) · 2023Review
- Functionalized Ultrasmall Iron Oxide Nanoparticles forMolecules (Basel, Switzerland) · 2022Article
- Article
- Effects of PEG Chain Length on Relaxometric Properties of Iron Oxide Nanoparticles-Based MRI Contrast Agent.Nanomaterials (Basel, Switzerland) · 2022Article
- Ultrasmall Superparamagnetic Iron Oxide Nanoparticles as Nanocarriers for Magnetic Resonance Imaging: Development andACS applied nano materials · 2022Article
- Recent advances in engineering iron oxide nanoparticles for effective magnetic resonance imaging.Bioactive materials · 2022Review
- Designing the Surface Chemistry of Inorganic Nanocrystals for Cancer Imaging and Therapy.Cancers · 2022Review
- A facile aqueous production of bisphosphonated-polyelectrolyte functionalized magnetite nanoparticles for pH-specific targeting of acidic-bone cells.RSC advances · 2022Article
- Aspects of high-performance and bio-acceptable magnetic nanoparticles for biomedical application.Asian journal of pharmaceutical sciences · 2021Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The efficient delivery of nanomaterials to specific targets for in vivo biomedical imaging is hindered by rapid sequestration by the reticuloendothelial system (RES) and consequent short circulation times. To overcome these two problems, we have prepared a new stealth PEG polymer conjugate containing a terminal 1,1-bisphosphonate (BP) group for strong and stable binding to the surface of ultrasmall-superparamagnetic oxide nanomaterials (USPIOs). This polymer, PEG(5)-BP, can be used to exchange the hydrophobic surfactants commonly used in the synthesis of USPIOs very efficiently and at room temperature using a simple method in 1 h. The resulting nanoparticles, PEG(5)-BP-USPIOs are stable in water or saline for at least 7 months and display a near-zero ζ-potential at neutral pH. The longitudinal (r(1)) and transverse (r(2)) relaxivities were measured at a clinically relevant magnetic field (3 T), revealing a high r(1) of 9.5 mM(-1) s(-1) and low r(2)/r(1) ratio of 2.97, making these USPIOs attractive as T1-weighted MRI contrast agents at high magnetic fields. The strong T1-effect was demonstrated in vivo, revealing that PEG(5)-BP-USPIOs remain in the bloodstream and enhance its signal 6-fold, allowing the visualization of blood vessels and vascular organs with high spatial definition. Furthermore, the optimal relaxivity properties allow us to inject a dose 4 times lower than with other USPIOs. PEG(5)-BP-USPIOs can also be labeled using a radiolabeled-BP for visualization with single photon emission computed tomography (SPECT), and thus affording dual-modality contrast. The SPECT studies confirmed low RES uptake and long blood circulation times (t(1/2) = 2.97 h). These results demonstrate the potential of PEG(5)-BP-USPIOs for the development of targeted multimodal imaging agents for molecular imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.